FDA approves Xolair (omalizumab) for people with Chronic Idiopathic Urticaria, a form of chronic hives

Roche today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for people 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Until now, H1-antihistamines have been the only approved therapy for CIU, with about 50 percent of patients having an inadequate response.

http://www.roche.com/media/media_releases/med-cor-2014-03-24.htm

Source: Roche Media News - March 24, 2014 Category: Pharmaceuticals Source Type: news

More News: Food and Drug Administration (FDA) | Hives | Pharmaceuticals | Xolair